Drug intelligence / Profile preview

olaparib + rucaparib + niraparib + talazoparib + veliparib + pamiparib + fluzoparib

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

This is a combination of seven PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, and fluzoparib). PARP inhibitors work by blocking DNA repair mechanisms in cancer cells, particularly those with deficiencies in homologous recombination repair such as BRCA1/2 mutations. They have varying potencies for PARP trapping, with talazoparib being the most potent, followed by niraparib, olaparib, and rucaparib. These drugs are primarily used in the treatment of ovarian, breast, and pancreatic cancers.

Targets

PARP2 (Poly (adp-ribose) polymerase 2)

Beyond the preview

Go deeper on olaparib + rucaparib + niraparib + talazoparib + veliparib + pamiparib + fluzoparib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on olaparib + rucaparib + niraparib + talazoparib + veliparib + pamiparib + fluzoparib.

Explore the full profile